Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test may predict lung surgery risks

NCT ID NCT07359885

Diagnosis Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to see if a blood test, taken before lung cancer surgery, can predict which patients will develop serious lung complications afterward. Researchers will analyze immune cells and proteins in the blood of 100 adults undergoing lung surgery. If the test works, it could help doctors take early steps to prevent complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test (immune cell and protein analysis)
What this could lead to
If successful, this could lead to a simple blood test that helps doctors identify patients at high risk of lung complications after surgery, allowing for better preventive care.
What could go wrong
This is a small, early-stage study (100 participants) that has not yet started recruiting. The test is still being developed and may not prove accurate enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing programmed video-assisted or robot-assisted lobectomy, bilobectomy or segmentectomy.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * ASA score ≤ 3 * Patients undergoing scheduled video-assisted or robot-assisted lobectomy, bilobectomy, or segmentectomy. * Patients who have read and understood the information letter and do not object to the research. * For women of childbearing age (non-sterile): effective contraception * Menopausal (non-medically induced amenorrhea for at least 12 months) * Patients covered by a social security scheme Exclusion Criteria: * Minor patients * Surgery scheduled for a Friday * Patients undergoing a pneumonectomy * Pregnant or breastfeeding women * Patients deprived of their liberty by an administrative or judicial decision, as well as those under legal protection, guardianship, or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postoperative pulmonary complications (PPCS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de Anesthésie-Réanimation Médecine périopératoire CHU de Rouen

    Rouen, 76100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.